NUR 2474 PHARMACOLOGY FOR NURSING EXAMINATION
Comprehensive Medication Management & Safe Administration Competency Assessment
Academic Year 2026/2027 | 75 Multiple-Choice Questions | 105 Minutes
EXAM INSTRUCTIONS
• Total Questions: 75 multiple-choice questions (MCQ) with four options (A, B, C, D), single-best-answer
format.
• Total Testing Time: 105 minutes. Pace yourself accordingly (approximately 1.4 minutes per question).
• Passing Score: Typically 75-80% required per program policy (56-60 correct answers out of 75).
• Calculator Policy: A basic calculator is permitted for dosage calculation items.
• For Select-All-That-Apply (SATA) items, clearly marked, select all options that apply.
• All questions are presented in bold; correct answers appear in bold purple (#BC13FE); rationales are in
italic font with lavender background.
• This exam is aligned with Lehne's Pharmacology for Nursing Care (11th ed.), Lilley's Pharmacology and
the Nursing Process (9th ed.), AACN Essentials, and ISMP High-Alert Medication Lists.
Domain Questions Points Each Total Points Score
Pharmacokinetics/Safety/ANS 1-21 1 21
Cardiovascular/Respiratory/GI 22-40 1 19
Endocrine/Neurologic/Infectives 41-61 1 21
TOTAL 1-75 1 75
DOMAIN 1: PHARMACOKINETICS & PHARMACODYNAMICS FUNDAMENTALS
ADME Processes | Half-Life & Steady-State | Bioavailability | Receptor Theory | Dose-Response Curves
1. A nurse is administering a medication that undergoes extensive first-pass metabolism.
Which route of administration would bypass this effect most effectively?
A. Oral B. Sublingual
C. Rectal D. Enteric-coated oral
Correct Answer: B
Rationale: The sublingual route allows the medication to be absorbed directly into the systemic circulation
through the highly vascularized mucosa under the tongue, thereby bypassing hepatic first-pass metabolism
entirely. Oral and rectal routes still subject the drug to partial or complete first-pass effect through the liver
via the portal circulation. Enteric-coated oral formulations protect the drug from stomach acid but do not
prevent first-pass metabolism once the drug is absorbed in the intestine and transported to the liver
through the hepatic portal vein.
2. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady-state
plasma concentration with repeated dosing?
A. 16 hours B. 24 hours
C. 40 hours D. 64 hours
Correct Answer: C
Rationale: Steady-state is reached after approximately 4-5 half-lives of repeated dosing. With a half-life of
8 hours, 5 half-lives equals 40 hours (8 x 5 = 40). At this point, the rate of drug administration equals the
rate of elimination, and plasma drug concentrations fluctuate within a consistent range between doses.
Understanding this concept is critical for nurses to know when to assess therapeutic effectiveness and when
to anticipate that a drug has reached its full therapeutic potential.
3. Which statement best describes the difference between potency and efficacy?
A. Potency refers to the maximum effect a drug can B. Potency refers to the dose needed to
produce; efficacy refers to the dose needed to produce a given effect; efficacy refers to the
produce an effect maximum effect a drug can produce
C. Potency and efficacy are interchangeable terms D. Potency describes drug safety; efficacy describes
describing the same pharmacologic property drug toxicity
Correct Answer: B
,Rationale: Potency refers to the amount of drug needed to produce a given effect — a more potent drug
requires a smaller dose to achieve the same effect. Efficacy refers to the maximum therapeutic effect a drug
can produce, regardless of dose. A drug can be highly potent (requires small doses) but have low efficacy
(cannot produce a strong maximal effect). Conversely, a drug may have low potency (requires larger
doses) but high efficacy (can produce a strong maximal effect). Both concepts are essential for clinical
decision-making in drug selection and dosing.
4. A partial agonist binds to the same receptor as a full agonist. What is the expected effect
when the partial agonist is administered concurrently with a full agonist?
A. Synergistic enhancement of the full agonist B. No change in the full agonist effect
effect
C. Diminished maximal effect compared to D. Complete blockade of the receptor
the full agonist alone
Correct Answer: C
Rationale: A partial agonist produces a submaximal response when bound to a receptor, even at full
receptor occupancy. When administered concurrently with a full agonist, the partial agonist competes for
the same receptor binding sites and activates them to a lesser degree, thereby reducing the overall maximal
response that could be achieved by the full agonist alone. This property makes partial agonists act as net
antagonists in the presence of a full agonist, which is clinically relevant for drugs like buprenorphine (a
partial mu-opioid agonist used in opioid dependence treatment).
5. Which pharmacokinetic process is primarily responsible for the conversion of a lipid-
soluble drug into a more water-soluble metabolite for renal excretion?
A. Absorption B. Distribution
C. Metabolism D. Excretion
Correct Answer: C
Rationale: Metabolism (biotransformation), primarily occurring in the liver through cytochrome P450
enzyme systems, converts lipid-soluble drugs into more water-soluble metabolites that can be eliminated
by the kidneys. This conversion is essential because lipid-soluble compounds would otherwise be
reabsorbed in the renal tubules and remain in the body. Absorption is the movement of drug from site of
administration into the blood, distribution is the movement of drug throughout body fluids and tissues, and
excretion is the removal of drug or metabolites from the body.
6. A patient is taking a drug that is highly protein-bound (98%). Another highly protein-bound
drug is added to the regimen. What is the nurse's primary concern?
A. Decreased therapeutic effect of both drugs B. Increased free drug concentration leading
to potential toxicity
C. Enhanced metabolism of both drugs D. Accelerated renal excretion of both drugs
Correct Answer: B
Rationale: When two highly protein-bound drugs are administered concurrently, they compete for binding
sites on plasma proteins (primarily albumin). This competition can displace one or both drugs from their
protein-binding sites, increasing the free (unbound) drug concentration in the plasma. Since only free drug
is pharmacologically active, this displacement can lead to enhanced drug effects or toxicity even though
total drug concentrations may appear normal. The nurse should monitor for signs of drug toxicity and
anticipate potential dose adjustments.
7. Bioavailability of a drug is defined as the:
A. Rate at which a drug is metabolized by the liver B. Fraction of the administered dose that
reaches the systemic circulation unchanged
C. Volume of distribution of the drug in body D. Time required for the drug to reach its peak
tissues plasma concentration
Correct Answer: B
Rationale: Bioavailability is defined as the fraction or percentage of the administered drug dose that
reaches the systemic circulation in its unchanged (active) form. For intravenous drugs, bioavailability is
100% since the drug is delivered directly into the bloodstream. For oral drugs, bioavailability is typically
less than 100% due to factors such as incomplete absorption, first-pass hepatic metabolism, and
degradation in the gastrointestinal tract. Understanding bioavailability is essential for dose calculations
when switching between routes of administration.
, DOMAIN 2: MEDICATION SAFETY & HIGH-ALERT DRUG PROTOCOLS
ISMP High-Alert Medications | Double-Check Procedures | BCMA Compliance | LASA Differentiation |
Error Reporting
8. According to the Institute for Safe Medication Practices (ISMP), which of the following is
classified as a high-alert medication?
A. Acetaminophen B. Insulin
C. Omeprazole D. Metformin
Correct Answer: B
Rationale: The ISMP classifies insulin as a high-alert medication because it carries a heightened risk of
causing significant patient harm when used in error. Insulin errors, such as dose miscalculation, wrong
type administered, or omitted doses, can lead to life-threatening hypoglycemia or hyperglycemia. High-
alert medications require special safeguards including independent double-checks, standardized
concentrations, and barcode verification. Acetaminophen, omeprazole, and metformin, while having
important safety considerations, are not classified as high-alert medications by the ISMP.
9. A nurse is preparing to administer heparin via IV infusion. Which safety practice is most
critical before administration?
A. Verifying the patient's blood glucose level B. Having a second nurse independently
verify the medication, dose, and pump
settings
C. Ensuring the patient has eaten a full meal D. Confirming the patient's allergy to shellfish
Correct Answer: B
Rationale: Heparin is an ISMP high-alert medication that requires independent double-verification before
administration. Having a second nurse independently verify the medication name, concentration, dose,
route, and IV pump settings is essential to prevent potentially fatal medication errors such as dosing
miscalculations, wrong concentration selection, or incorrect infusion rates. This two-nurse verification
process serves as a critical safety barrier. Blood glucose monitoring is relevant for insulin, not heparin.
Meal intake is unrelated to heparin administration, and shellfish allergy is relevant for iodine-based
contrast, not heparin.
10. The nurse is using Barcode Medication Administration (BCMA) technology. Which action
demonstrates proper BCMA compliance?
A. Scanning the medication barcode before B. Scanning the patient identification
scanning the patient identification bracelet bracelet first, then scanning the medication
barcode
C. Scanning only the medication barcode and D. Administering the medication first, then
proceeding with administration scanning the barcode afterward for documentation
Correct Answer: B
Rationale: Proper BCMA compliance requires scanning the patient identification bracelet first to verify the
patient's identity, followed by scanning the medication barcode. This sequence ensures the five rights of
medication administration (right patient, right drug, right dose, right route, right time) are verified
through the electronic system before the drug is administered. Scanning only the medication without the
patient ID, or scanning after administration, defeats the purpose of BCMA as a point-of-care safety check
designed to prevent errors before they reach the patient.
11. Which of the following is an example of a Look-Alike/Sound-Alike (LASA) drug pair that
poses a significant safety risk?
A. Amoxicillin and Azithromycin B. Hydroxyzine and Hydralazine
C. Metoprolol and Metformin D. Lisinopril and Losartan
Correct Answer: B
Rationale: Hydroxyzine (an antihistamine) and hydralazine (an antihypertensive) are a well-known LASA
drug pair because their names look and sound very similar, yet they have completely different
pharmacologic actions and indications. Confusing these medications could result in a patient receiving an
antihistamine when an antihypertensive is needed, or vice versa, potentially leading to untreated
hypertension or unnecessary sedation. Strategies to differentiate LASA drugs include using Tall Man
lettering (hydrOXYzine vs. hydrALAZINE), storing them in separate locations, and using both generic and
brand names on labels.
Comprehensive Medication Management & Safe Administration Competency Assessment
Academic Year 2026/2027 | 75 Multiple-Choice Questions | 105 Minutes
EXAM INSTRUCTIONS
• Total Questions: 75 multiple-choice questions (MCQ) with four options (A, B, C, D), single-best-answer
format.
• Total Testing Time: 105 minutes. Pace yourself accordingly (approximately 1.4 minutes per question).
• Passing Score: Typically 75-80% required per program policy (56-60 correct answers out of 75).
• Calculator Policy: A basic calculator is permitted for dosage calculation items.
• For Select-All-That-Apply (SATA) items, clearly marked, select all options that apply.
• All questions are presented in bold; correct answers appear in bold purple (#BC13FE); rationales are in
italic font with lavender background.
• This exam is aligned with Lehne's Pharmacology for Nursing Care (11th ed.), Lilley's Pharmacology and
the Nursing Process (9th ed.), AACN Essentials, and ISMP High-Alert Medication Lists.
Domain Questions Points Each Total Points Score
Pharmacokinetics/Safety/ANS 1-21 1 21
Cardiovascular/Respiratory/GI 22-40 1 19
Endocrine/Neurologic/Infectives 41-61 1 21
TOTAL 1-75 1 75
DOMAIN 1: PHARMACOKINETICS & PHARMACODYNAMICS FUNDAMENTALS
ADME Processes | Half-Life & Steady-State | Bioavailability | Receptor Theory | Dose-Response Curves
1. A nurse is administering a medication that undergoes extensive first-pass metabolism.
Which route of administration would bypass this effect most effectively?
A. Oral B. Sublingual
C. Rectal D. Enteric-coated oral
Correct Answer: B
Rationale: The sublingual route allows the medication to be absorbed directly into the systemic circulation
through the highly vascularized mucosa under the tongue, thereby bypassing hepatic first-pass metabolism
entirely. Oral and rectal routes still subject the drug to partial or complete first-pass effect through the liver
via the portal circulation. Enteric-coated oral formulations protect the drug from stomach acid but do not
prevent first-pass metabolism once the drug is absorbed in the intestine and transported to the liver
through the hepatic portal vein.
2. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady-state
plasma concentration with repeated dosing?
A. 16 hours B. 24 hours
C. 40 hours D. 64 hours
Correct Answer: C
Rationale: Steady-state is reached after approximately 4-5 half-lives of repeated dosing. With a half-life of
8 hours, 5 half-lives equals 40 hours (8 x 5 = 40). At this point, the rate of drug administration equals the
rate of elimination, and plasma drug concentrations fluctuate within a consistent range between doses.
Understanding this concept is critical for nurses to know when to assess therapeutic effectiveness and when
to anticipate that a drug has reached its full therapeutic potential.
3. Which statement best describes the difference between potency and efficacy?
A. Potency refers to the maximum effect a drug can B. Potency refers to the dose needed to
produce; efficacy refers to the dose needed to produce a given effect; efficacy refers to the
produce an effect maximum effect a drug can produce
C. Potency and efficacy are interchangeable terms D. Potency describes drug safety; efficacy describes
describing the same pharmacologic property drug toxicity
Correct Answer: B
,Rationale: Potency refers to the amount of drug needed to produce a given effect — a more potent drug
requires a smaller dose to achieve the same effect. Efficacy refers to the maximum therapeutic effect a drug
can produce, regardless of dose. A drug can be highly potent (requires small doses) but have low efficacy
(cannot produce a strong maximal effect). Conversely, a drug may have low potency (requires larger
doses) but high efficacy (can produce a strong maximal effect). Both concepts are essential for clinical
decision-making in drug selection and dosing.
4. A partial agonist binds to the same receptor as a full agonist. What is the expected effect
when the partial agonist is administered concurrently with a full agonist?
A. Synergistic enhancement of the full agonist B. No change in the full agonist effect
effect
C. Diminished maximal effect compared to D. Complete blockade of the receptor
the full agonist alone
Correct Answer: C
Rationale: A partial agonist produces a submaximal response when bound to a receptor, even at full
receptor occupancy. When administered concurrently with a full agonist, the partial agonist competes for
the same receptor binding sites and activates them to a lesser degree, thereby reducing the overall maximal
response that could be achieved by the full agonist alone. This property makes partial agonists act as net
antagonists in the presence of a full agonist, which is clinically relevant for drugs like buprenorphine (a
partial mu-opioid agonist used in opioid dependence treatment).
5. Which pharmacokinetic process is primarily responsible for the conversion of a lipid-
soluble drug into a more water-soluble metabolite for renal excretion?
A. Absorption B. Distribution
C. Metabolism D. Excretion
Correct Answer: C
Rationale: Metabolism (biotransformation), primarily occurring in the liver through cytochrome P450
enzyme systems, converts lipid-soluble drugs into more water-soluble metabolites that can be eliminated
by the kidneys. This conversion is essential because lipid-soluble compounds would otherwise be
reabsorbed in the renal tubules and remain in the body. Absorption is the movement of drug from site of
administration into the blood, distribution is the movement of drug throughout body fluids and tissues, and
excretion is the removal of drug or metabolites from the body.
6. A patient is taking a drug that is highly protein-bound (98%). Another highly protein-bound
drug is added to the regimen. What is the nurse's primary concern?
A. Decreased therapeutic effect of both drugs B. Increased free drug concentration leading
to potential toxicity
C. Enhanced metabolism of both drugs D. Accelerated renal excretion of both drugs
Correct Answer: B
Rationale: When two highly protein-bound drugs are administered concurrently, they compete for binding
sites on plasma proteins (primarily albumin). This competition can displace one or both drugs from their
protein-binding sites, increasing the free (unbound) drug concentration in the plasma. Since only free drug
is pharmacologically active, this displacement can lead to enhanced drug effects or toxicity even though
total drug concentrations may appear normal. The nurse should monitor for signs of drug toxicity and
anticipate potential dose adjustments.
7. Bioavailability of a drug is defined as the:
A. Rate at which a drug is metabolized by the liver B. Fraction of the administered dose that
reaches the systemic circulation unchanged
C. Volume of distribution of the drug in body D. Time required for the drug to reach its peak
tissues plasma concentration
Correct Answer: B
Rationale: Bioavailability is defined as the fraction or percentage of the administered drug dose that
reaches the systemic circulation in its unchanged (active) form. For intravenous drugs, bioavailability is
100% since the drug is delivered directly into the bloodstream. For oral drugs, bioavailability is typically
less than 100% due to factors such as incomplete absorption, first-pass hepatic metabolism, and
degradation in the gastrointestinal tract. Understanding bioavailability is essential for dose calculations
when switching between routes of administration.
, DOMAIN 2: MEDICATION SAFETY & HIGH-ALERT DRUG PROTOCOLS
ISMP High-Alert Medications | Double-Check Procedures | BCMA Compliance | LASA Differentiation |
Error Reporting
8. According to the Institute for Safe Medication Practices (ISMP), which of the following is
classified as a high-alert medication?
A. Acetaminophen B. Insulin
C. Omeprazole D. Metformin
Correct Answer: B
Rationale: The ISMP classifies insulin as a high-alert medication because it carries a heightened risk of
causing significant patient harm when used in error. Insulin errors, such as dose miscalculation, wrong
type administered, or omitted doses, can lead to life-threatening hypoglycemia or hyperglycemia. High-
alert medications require special safeguards including independent double-checks, standardized
concentrations, and barcode verification. Acetaminophen, omeprazole, and metformin, while having
important safety considerations, are not classified as high-alert medications by the ISMP.
9. A nurse is preparing to administer heparin via IV infusion. Which safety practice is most
critical before administration?
A. Verifying the patient's blood glucose level B. Having a second nurse independently
verify the medication, dose, and pump
settings
C. Ensuring the patient has eaten a full meal D. Confirming the patient's allergy to shellfish
Correct Answer: B
Rationale: Heparin is an ISMP high-alert medication that requires independent double-verification before
administration. Having a second nurse independently verify the medication name, concentration, dose,
route, and IV pump settings is essential to prevent potentially fatal medication errors such as dosing
miscalculations, wrong concentration selection, or incorrect infusion rates. This two-nurse verification
process serves as a critical safety barrier. Blood glucose monitoring is relevant for insulin, not heparin.
Meal intake is unrelated to heparin administration, and shellfish allergy is relevant for iodine-based
contrast, not heparin.
10. The nurse is using Barcode Medication Administration (BCMA) technology. Which action
demonstrates proper BCMA compliance?
A. Scanning the medication barcode before B. Scanning the patient identification
scanning the patient identification bracelet bracelet first, then scanning the medication
barcode
C. Scanning only the medication barcode and D. Administering the medication first, then
proceeding with administration scanning the barcode afterward for documentation
Correct Answer: B
Rationale: Proper BCMA compliance requires scanning the patient identification bracelet first to verify the
patient's identity, followed by scanning the medication barcode. This sequence ensures the five rights of
medication administration (right patient, right drug, right dose, right route, right time) are verified
through the electronic system before the drug is administered. Scanning only the medication without the
patient ID, or scanning after administration, defeats the purpose of BCMA as a point-of-care safety check
designed to prevent errors before they reach the patient.
11. Which of the following is an example of a Look-Alike/Sound-Alike (LASA) drug pair that
poses a significant safety risk?
A. Amoxicillin and Azithromycin B. Hydroxyzine and Hydralazine
C. Metoprolol and Metformin D. Lisinopril and Losartan
Correct Answer: B
Rationale: Hydroxyzine (an antihistamine) and hydralazine (an antihypertensive) are a well-known LASA
drug pair because their names look and sound very similar, yet they have completely different
pharmacologic actions and indications. Confusing these medications could result in a patient receiving an
antihistamine when an antihypertensive is needed, or vice versa, potentially leading to untreated
hypertension or unnecessary sedation. Strategies to differentiate LASA drugs include using Tall Man
lettering (hydrOXYzine vs. hydrALAZINE), storing them in separate locations, and using both generic and
brand names on labels.
